Sexually Transmitted Diseases 1997: Vol 24 Index

7 Pages·1997·1.5 MB·English

Index to Volume Twenty-four
Index of Issues: January, 1-60; February, 61-120; March, 121-180; April, 181-240; May, 241-311;
July, 313-386; August, 387-442; September, 443-494; October, 495-554; November, 555-614.
INDEX OF AUTHORS
A Changalucha J, 121 F Hoosen AA, 18
Chearskul S, 495 Houang ET, 116
Adjovi C, 109 Falck RS, 204
Chenia HY, 18 Howell MR, 287
Aebischer F, 69 Farley, TA, 227
Chernesky MA, 61 Hoyle DV, 185
Agacfidan A, 573 Faulkner PL, 503
Chiang CS, 176 Hughes JP, 272, 449
Ahmet Z, 116 Fennema JSA, 363
Alary M, 109 Chitwarakorn A, 142 Fife KH, 481, 555 Huovinen P, 576
Allaire G, 23 Chotpitayasunondh T, 495 Fine D, 131 Hwang L-Y, 475
Chow JM, 573
Amortegui AJ, 38 Finnish Study Group For Antimi-
Anderson RM, 185 Chuachoowong R, 495 crobial Resistance, 576 I
Anderson, L, 347 Ciemins EL, 422 Flemetakis A, 378 lida M, 284
Angamuthu V, 251 Clarke P, 443, 599 Fonseca K, 487 Irwin DE, 372
Ankrah EM, 550 Code K, 599 Ford K, 327 Iwasawa A, 165
Apter D, 343 Conde-Glez CJ, 211 Forster GE, 127
Aral SO, 185, 299 Cordero E, 422 Fortenberry JD, 261, 313, 555 J
AAABrsvavhgdileuedrrysi onnSo,R u L ,5M 7,BH3 , 1 44193 878 CCCCCCCoooooortruuuaucetrtbrhlytiby é nné-eeh DM Lyoo,F F nF,,,i J1R g3G4A232,9e,35 r 3 4 326P2,3 587 FFFFFForrrrrexaeiis nyeeig ddaRo mm,Rua aLlAnn,i4, 3 644LSE 60S,R12 ,, 3793802 2 JJJJJJaaaaoaccldhryokvak bsiocsnolkJ ena Rn ,B R ,MDA H,1,,,0 1 9225 41567 077626
Balamotis A, 469 Crescimbeni E, 533 G Jose B, 322
Barbarash RA, 481 Crowe G, 127 Judrez-Figueroa LA, 211
Bearinger LH, 503 Cuan J, 176 Garnett GP, 45, 185 Judson FN, 429
Beauvais B, 293 Culpepper-Morgan J, 322 Gentili G, 533
Belongia EA, 251 Germaine M, 109 K
Curtis R, 322
Berbik I, 538 Ghadirian P, 23
Cyr WH, 161 Ka-Gina G, 121
Berege ZA, 121 Ghani AC, 45
Kallings I, 418
Berman SM, 169 Ghattas G, 23
Beyrer C, 546 D Ghys P, 32 Kalogeropoulou A, 378
Kalpaktsoglou K, 469
Bhadrakom C, 495 Gibbs RS, 353
Dailianas S, 469 Kanematsu E, 247
Black CM, 299 Giglio A, 533
Dalby DM, 393 Kassler WJ, 287
Blander SJ, 38 Ginsberg MM, 347
Danila RN, 251 Katz BP, 313
Blank S, 218 Giuliani M, 533
Danzig MR, 156 Katz MH, 347
Bleker OP, 456 Goh BT, 127
Davo N, 109 Kaul R, 387
Blythe MJ, 261, 313 Grant I 398
de Boer MA, 546 Kawada Y, 247, 284
Bock JE, 567 Deak J, 538 Greenspan JR, 218 Kellogg T, 347
Boer K, 456 Gross TP, 11
DeBoer JM, 251 Kilmarx PH, 593
Bogaerts J, 32 Grosskurth H, 121
Degregorio B, 481 Kimani J, 387
Bolan G, 176, 443, 599 Guédémé A, 109
Deguchi K, 247 Kjaer SK, 567
Bollen LJM, 456 Gunn RA, 90
Borenstein LA, 422 Deguchi T, 247, 284 Klebanoff MA, 353
del Rio-Chiriboga C, 211 Knapp JS, 2, 142
BBorirzge nLd,i n3e2 2 EJ, 313 DeLisle S, 131 H Komeda H, 284
Brome MW, 218 Des Jarlais DC, 320, 322 Haddix A, 287 Korattana S, 593
Brookmeyer R, 436 Desmyter J, 94 Handsfield HH, 131, 272, 449 Koutsky L, 149
Brunham RC, 387 Dewet GH, 94 Harvey SM, 422 Kovacs L, 538
Buatiang A, 142 Diakomanolis E, 469 Hayasaki M, 284 Kreek MJ, 322
Bushar HF, 161 Diallo M, 32 Heaton RK, 398 Kreiss JK, 267, 279
Bwayo J, 267, 387 Dicker LW, 511 Hellberg D, 241, 418 Krohn MA, 353
Dixon LG, 161 Krone M, 599
Henry K, 443, 599
Dixon, PB, 229 Hernandez-Avila M, 211 Ku L, 299
Cc Donders G, 94 Hernandez-Nevarez P, 211 Kyriakis KP, 378
Dorian KJ, 169
Herne K, 555
Campbell PJ, 487 Douglas JM, 555 Hickman CD, 251 L
Caprilli F, 533 Douglas JM, Jr, 429 Hillier SL, 353 Labropoulou V, 469
Carey JC, 353 duBouchet L, 156 Hillis SD, 131 Lafferty WE, 272, 449
Carlson RG, 204 Dussaix E, 582 Hiltunen-Back E, 165 Laga M, 32
Carolina J, 511 Dyer IE, 422 Hirvonen S, 343 Landis SJ, 393
Carré N, 582 Hollins L, 475 Lawlor JP, 436
E
Cates W Jr., 185 Holmes KK, 561 Lawrence AG, 116
Celentano DD, 546 Edelman R, 353 Hooft P, 94 Leduc R, 23
Celum CL, 131, 443, 599 Ehret JM, 429 Hook EW III, 181, 229, 599, 372, Leonard L, 475
Chaisilwattana P, 495 Eschenbach DA, 353 436, 443 Leone P, 443
Index to Volume Twenty-four
Index of Issues: January, 1-60; February, 61-120; March, 121-180; April, 181-240; May, 241-311;
July, 313-386; August, 387-442; September, 443-494; October, 495-554; November, 555-614.
INDEX OF AUTHORS
A Changalucha J, 121 F Hoosen AA, 18
Chearskul S, 495 Houang ET, 116
Adjovi C, 109 Falck RS, 204
Chenia HY, 18 Howell MR, 287
Aebischer F, 69 Farley, TA, 227
Chernesky MA, 61 Hoyle DV, 185
Agacfidan A, 573 Faulkner PL, 503
Chiang CS, 176 Hughes JP, 272, 449
Ahmet Z, 116 Fennema JSA, 363
Alary M, 109 Chitwarakorn A, 142 Fife KH, 481, 555 Huovinen P, 576
Allaire G, 23 Chotpitayasunondh T, 495 Fine D, 131 Hwang L-Y, 475
Chow JM, 573
Amortegui AJ, 38 Finnish Study Group For Antimi-
Anderson RM, 185 Chuachoowong R, 495 crobial Resistance, 576 I
Anderson, L, 347 Ciemins EL, 422 Flemetakis A, 378 lida M, 284
Angamuthu V, 251 Clarke P, 443, 599 Fonseca K, 487 Irwin DE, 372
Ankrah EM, 550 Code K, 599 Ford K, 327 Iwasawa A, 165
Apter D, 343 Conde-Glez CJ, 211 Forster GE, 127
Aral SO, 185, 299 Cordero E, 422 Fortenberry JD, 261, 313, 555 J
AAABrsvavhgdileuedrrysi onnSo,R u L ,5M 7,BH3 , 1 44193 878 CCCCCCCoooooortruuuaucetrtbrhlytiby é nné-eeh DM Lyoo,F F nF,,,i J1R g3G4A232,9e,35 r 3 4 326P2,3 587 FFFFFForrrrrexaeiis nyeeig ddaRo mm,Rua aLlAnn,i4, 3 644LSE 60S,R12 ,, 3793802 2 JJJJJJaaaaoaccldhryokvak bsiocsnolkJ ena Rn ,B R ,MDA H,1,,,0 1 9225 41567 077626
Balamotis A, 469 Crescimbeni E, 533 G Jose B, 322
Barbarash RA, 481 Crowe G, 127 Judrez-Figueroa LA, 211
Bearinger LH, 503 Cuan J, 176 Garnett GP, 45, 185 Judson FN, 429
Beauvais B, 293 Culpepper-Morgan J, 322 Gentili G, 533
Belongia EA, 251 Germaine M, 109 K
Curtis R, 322
Berbik I, 538 Ghadirian P, 23
Cyr WH, 161 Ka-Gina G, 121
Berege ZA, 121 Ghani AC, 45
Kallings I, 418
Berman SM, 169 Ghattas G, 23
Beyrer C, 546 D Ghys P, 32 Kalogeropoulou A, 378
Kalpaktsoglou K, 469
Bhadrakom C, 495 Gibbs RS, 353
Dailianas S, 469 Kanematsu E, 247
Black CM, 299 Giglio A, 533
Dalby DM, 393 Kassler WJ, 287
Blander SJ, 38 Ginsberg MM, 347
Danila RN, 251 Katz BP, 313
Blank S, 218 Giuliani M, 533
Danzig MR, 156 Katz MH, 347
Bleker OP, 456 Goh BT, 127
Davo N, 109 Kaul R, 387
Blythe MJ, 261, 313 Grant I 398
de Boer MA, 546 Kawada Y, 247, 284
Bock JE, 567 Deak J, 538 Greenspan JR, 218 Kellogg T, 347
Boer K, 456 Gross TP, 11
DeBoer JM, 251 Kilmarx PH, 593
Bogaerts J, 32 Grosskurth H, 121
Degregorio B, 481 Kimani J, 387
Bolan G, 176, 443, 599 Guédémé A, 109
Deguchi K, 247 Kjaer SK, 567
Bollen LJM, 456 Gunn RA, 90
Borenstein LA, 422 Deguchi T, 247, 284 Klebanoff MA, 353
del Rio-Chiriboga C, 211 Knapp JS, 2, 142
BBorirzge nLd,i n3e2 2 EJ, 313 DeLisle S, 131 H Komeda H, 284
Brome MW, 218 Des Jarlais DC, 320, 322 Haddix A, 287 Korattana S, 593
Brookmeyer R, 436 Desmyter J, 94 Handsfield HH, 131, 272, 449 Koutsky L, 149
Brunham RC, 387 Dewet GH, 94 Harvey SM, 422 Kovacs L, 538
Buatiang A, 142 Diakomanolis E, 469 Hayasaki M, 284 Kreek MJ, 322
Bushar HF, 161 Diallo M, 32 Heaton RK, 398 Kreiss JK, 267, 279
Bwayo J, 267, 387 Dicker LW, 511 Hellberg D, 241, 418 Krohn MA, 353
Dixon LG, 161 Krone M, 599
Henry K, 443, 599
Dixon, PB, 229 Hernandez-Avila M, 211 Ku L, 299
Cc Donders G, 94 Hernandez-Nevarez P, 211 Kyriakis KP, 378
Dorian KJ, 169
Herne K, 555
Campbell PJ, 487 Douglas JM, 555 Hickman CD, 251 L
Caprilli F, 533 Douglas JM, Jr, 429 Hillier SL, 353 Labropoulou V, 469
Carey JC, 353 duBouchet L, 156 Hillis SD, 131 Lafferty WE, 272, 449
Carlson RG, 204 Dussaix E, 582 Hiltunen-Back E, 165 Laga M, 32
Carolina J, 511 Dyer IE, 422 Hirvonen S, 343 Landis SJ, 393
Carré N, 582 Hollins L, 475 Lawlor JP, 436
E
Cates W Jr., 185 Holmes KK, 561 Lawrence AG, 116
Celentano DD, 546 Edelman R, 353 Hooft P, 94 Leduc R, 23
Celum CL, 131, 443, 599 Ehret JM, 429 Hook EW III, 181, 229, 599, 372, Leonard L, 475
Chaisilwattana P, 495 Eschenbach DA, 353 436, 443 Leone P, 443
Vol. 24 ¢ No. 10 INDEX OF AUTHORS
Leone P, 599 Nilsson U, 241 Roberts MC, 561 Toma E, 23
Leone PA, 372 Nishino Y, 247 Rodrigues I, 23 Toomey KE, 511
Lepri AC, 533 Nissinen A, 576 Romanowski B, 487 Tovanabutra S, 546
LeRoux T, 429 Norris, A, 327 Rompalo AM, 402, 436 Trottier A, 23
Levine WC, 169 Nugent RP, 353 Ronald A, 387 Tuazon, C, 2
Liimatainen O, 576 Nuntakuang D, 546 Ross M, 475 Turmel B, 23
Limpakarnjanarat K, 142, 593 Nyange PM, 279 Roth R, 481 Turner CF, 299, 522
Lytle CD, 161 Nyari T, 538 Rothenberg R, 201 Tyring SK, 555
Nzila N, 32 Routson LB, 161 Tzelepi E, 378
M Rubin SR, 218 Tzouvelekis LS, 378
O Rudolph T, 481
MacDonald KL, 251 Rugamba D, 279
MacEachern A, 84 Obongo T, 267 Rugpao S, 546 U
MacLean I, 267 Oldfield EC, III, 398
Uno M, 284
Magnus P, 102 Onorato IM, 461 S Urban MA. 587
Mahony JB, 109 Orr DP, 261, 313
Uribe-Salas FJ, 211
Maini A, 533 Ortiz CG, 429 Sadler R, 181
Malone JL, 398 Osterholm MT, 251 Safrin S, 176 Uribe-Zuiiga P, 211
Manalastas TR, 2 Ozarmagan G, 573 Saito I, 247
Mandaliya K, 267, 279 Ozeki S, 247 Salmon-Ceron D, 582 Vv
Mangclaviraj Y, 495 Sanche G, 23
Mardh P-A, 418, 241 P Sato K, 247 Vaginal Infections and
Marrazo JM, 131 Saurina GR, 361 Valaciclovir International Herpes
Martin DH, 353, 372 Paavonen J, 165, 343 Schachter J, 1 Simplex Virus Study
Martin HL Jr, 279 Padonou F, 109 Schwarcz SK, 347 Group, 481
Maruti S, 475 Paffel J, 475 Schwartz MA, 449 Van Ameijden EJC, 363
Masterson MB, 218 Palamara G, 533 Schwebke JR, 181, 236, 372 van de Laar MJW, 334, 409
Mastro TD, 142, 495, 593 Paone D, 322 Seaborn GB, 161 van den Hoek A, 334, 363
Mavromara P, 469 Parekh MC, 142 Sellors JW, 393 van der Meijden WI, 409
Parks KS, 229
Mayaud P, 121 SEROCO Study Group, 582 van der Velden J, 456
Pashazade H, 573
Mbengeranwa L, 528 Shaffer N, 495 van Duynhoven YTHP, 409
Pastorek JG II, 353
McCombs SB, 461 Sharma R, 543 Van Dyck E, 32, 109
Paukku M, 343
McCormack M, 156 Shaw H, 176 Van Klingeren B, 409
Peek M, 8
McCormack WM, 361, 543 Shepherd M, 436 van Santen-Verheuvel MG, 409
McCray E, 461 Perine PL, 2 Shew ML, 503 Veinbergs E, 90
McCutchan JA, 398 Peterman TA, 511 Shoubnikova M, 241 Velin R, 398
McDonnell DD, 218 Pickard L, 393 Siegal HA, 204 Veréb I, 538
MMccNDiocuogla llP , J2K9,3 69 PPiilclkaeyr inBg, 1J8, 543 SSiirlivwearsmiann WB,G ,4 951 1 Vongchak T, 546
Meng CY, 257 Pillay D, 18 Smith H, 267 Ww
Mertz KJ, 169 Plummer FA, 387 Smith M, 443, 599
Mesola VP, 2 Poll P, 567 Sokal D, 550 Wald A, 149
Mészaros G, 538 Potterat JJ, 519 Sonenstein FL, 299 Wallace MR, 398
Meyer L, 582 Potthoff SJ, 503 Spalding C, 443, 599 Wang J, 204
Miller HG, 522 Preiksaitis JK, 487 Spence MR, 156 Weiss HL, 236
Miller LK, 398 Prematurity Study Group, 353 Spitters C, 347, 372 Weiss PJ, 398
Mol BW, 456 Prignano G, 533 St Louis ME, 593 Wellington M, 528
Montstream SA, 429 Puolakkainen M, 343 Stevens CE, 279 Whittington WL, 2, 561
Morgan SC, 236 Stevenson E, 84 Wi TE, 2
Moses S, 267 Q Stigum H, 102 Wongba C, 142
Mosure DJ, 169 Stratton JD, 372 Wroten JE, 511
Munk C, 567 Quinn TC, 436 Sturm AW, 64
Munyabikali J, 32 R Suan KA, 257 xX
Suligoi B, 77
Xia M, 561
N Rakwar J, 267 Supavitkul S, 593
Rand S, 436 Sutton JM, 181
Nagatani M, 284 Rao AV, 353 Svare El, 567 Y
Nagelkerke NJD, 387 Regan JA, 353 Swinton J, 45
Yamaguchi KJ, 429
Nagy E, 538 Reichman RC, 587
T Yasin RM, 257
Nakano M, 247 Rein MF, 156
Yasuda M, 247
Ndinya-Achola J, 267, 279 Remafedi GJ, 503 Tanaka M, 247
Young NL, 142, 495, 293
Ndowa F, 528 Resnick MD, 503 Taylor BA, 503
Yutabootr Y, 546
Neaigus A, 322 Reunala T, 165 ten Kate FJW, 456
Neal JJ, 218 Rezza G, 533 ter Schegget J, 456 Z
Neal SW, 2, 142 Rhoads GG, 353 Termorshuizen F, 334
Nelson J, 398 Richardson BA, 279 Theodore C, 127 Zaidi AA, 511
Nelson KE, 546 Richey CM, 229, 443 Thomas JC, 372 Zenilman J, 8, 310, 322, 372, 402,
Ngugi EN, 387 Richwald GA, 422 Thompson SC, 84 436
Nieminen P, 165 Rietmeijer CA, 429 Tjong-A-Hung SP, 456 Zenilman JM, 310, 372
Nilsson S, 241, 418 Robain M, 582 Todd J, 121 Zimet GD, 555
610 INDEX OF SUBJECTS Sexually Transmitted Diseases ¢ November, 1997
A interferon-gamma and interleukin-5 in, 38
in low-risk population, in Hungary, 538
Aboriginal women, HPV infection in, vs. in non-Aboriginal women,
notification of, in Australia, 84
in Canada, 293
partner notification for, for PID prevention, 287
Adolescents
partner referral by patients with, 334
female, validityof self-reported sexual behavior in, 261
PCR test for, urine tests for, 343, 429
minority, sexual networks of, 327
in pregnant women, in Thailand, 495
prevention measures for, 90
substance use and sexual behavior in prevalence trends for, 169
in females, 313, 320 (editorial) screening for
in high-risk neighborhoods, 322 algorithm for, for high-risk groups in developing countries, 109
validity of self-reported condom use in, 503 in men, 587
Africa noncompliance with follow-up recommendations after, 181
performance and cost-effectiveness of, 131
Kenya
in Turkish sex workers, 573
female sex workers in, safety of nonoxynol-9 vaginal gel in, 279
sexual behavior risk factors for, 241
genital ulcer disease in, in prostitutes, 387
truck drivers in, H. ducreyi antibody in, 267 spontaneous clearance of, in untreated patients, 229
N. gonorrhoeae drug resistance in, 11, 32 surveillance of, laboratory compliance and, 84
Tanzania, sexual transmission of hepatitis B in, 121 Ciprofloxacin, N. gonorrhoeae resistance to, in Phillipines, 2
Zimbabwe, STD risk factors in, 528 Clinic patients. See also Sexually transmitted disease clinics
African Americans delayed treatment-seeking by, 443
adolescent, sexual networks of, 327 motivation for HIV testing in, 347
gestational trichomoniasis in, low birth weight and preterm delivery Clotrimazole, topical, for trichomoniasis, vs. oral metronidazole, 156
and, 353 Cocaine, condom use and, 204
motivation for HIV testing in, 347 Cognitive impairment, in HIV infection, STD history and, 398
AIDS dementia, STD history and, 398 Commercial sex workers
Alcohol use/abuse, sexual behavior and, in female adolescents, 313, chlamydial infection in, screening for, in Turkey, 573
320 (editorial) drug-using, STD incidence trends for, 363
Allantoin, in AVC suppositories, for trichomoniasis, vs. oral metroni- gonorrhea/chlamydia screening algorithm for, in developing countries,
dazole, 156 109
Aminacrine, in AVC suppositories, for trichomoniasis, vs. oral Kenyan
metronidazole, 156
genital ulcer disease in, 387
Anal intercourse, condoms in, 11 safety of nonoxynol-9 vaginal gel in, 279
Antibiotics. See Antimicrobials multiple condom use by, in Thailand, 546, 550 (editorial)
Anti-HBc, in HIV test seekers, 211 self-medication for STDs in, in Thailand, 593
Antimicrobial resistance. See Drug resistance/susceptibility Compliance, with daily procaine penicillin injections, for syphilis-tre-
Antimicrobials ponemal infection, 127
resistance to. See Drug resistance/susceptibility Condoms
for syphilis, 227 (editorial) in anal intercourse, 11
Australia, notification of chlamydial infection in, 84
failure to use, reasons for, 402
AVC suppositories, for trichomoniasis, vs. oral metronidazole, 156
multiple, use of, 550 (editorial)
Azithromycin
by commercial sex workers, in Thailand, 546, 550 (editorial)
N. gonorrhoeae susceptibility to, E-test vs. agar dilution methods for,
self-reported use of, validity of, 522
257
in adolescents, 503
for nongonococcal urethritis, 57 (letter)
as small virus barriers, 161
use of by heterosexual drug users, 204
B Condylomata acuminata. See also Human papillomavirus infection
in females, risk factors for, 567
Bacterial vaginosis, self-obtained sequential vaginal smears for, utility
of, 236 in males, HPV DNA in urine in, 165
Contact tracing. See Partner notification
Behavioral surveys, with integrated STD testing, 299, 552 (letter)
Crack cocaine, condom use and, 204
Benzathine penicillin, single injection of, for syphilis, in pregnancy,
94 Cultures
vs. DNA probe test, for N. gonorrhoeae, 422
organotypic raft, in evaluation of vaginal microbicidal agents, 69
Cc
virus, vs. PCR, for HSV infection diagnosis, 176
Canada Cytomegalovirus, seropositivity for, in HIV-infected men, sexual be-
HIV seroprevalence in, risk behaviors and, 487 havior and, 582
HPV infection in Aboriginal vs. non-Aboriginal women in, 293
physicians’ management of STDs in, 393 D
Cancer, cervical, type-specific prevalence of HPV in, in Greece, 469
Casual travel sex, high-risk behavior and, 418 Dementia, AIDS, STD history and, 398
Central Africa, N. gonorrhoeae resistance in, 32 Developing countries. See also specific countries
Cervical cancer, type-specific prevalence of HPV in, in Greece, 469 screening algorithm for gonorrhea and chlamydia in, 109
Cervical dysplasia, treatment of, clearance of HPV infection by, 456 STDs in, public-private initiatives for, 61 (editorial)
Cervical Mycoplasma genitalium, in Japan, 284 DNA probe test, vs. culture, for N. gonorrhoeae, 422
Chancroid, H. ducreyi virulence in, iron and, 64 Drug abuse. See Substance use/abuse
Chlamydia trachomatis infection Drug resistance/susceptibility, of N. gonorrhoeae, 247
Vol. 24 ¢ No. 10 INDEX OF SUBJECTS
in Finland, 573 demographic and sexual correlates of, 149
in Greece, 378 diagnosis of, virus culture vs. PCR for, 176
molecular epidemiology and, 409 first-episode, Valacyclovir vs. acyclovir for, 481
in Phillipines, 2 immunization for, acceptability of, 555
in South Africa, 11 High-risk behavior. See also Risk factors; Sexual behavior
in Thailand, 142 in women with history of casual travel sex, 418
in West and Central Africa, 32 Hispanic adolescents, sexual networks of, 327
Homosexuals, male, acquisition of gonorrhea and nongonococcal ure-
thritis by fellatio in, 272
E Hormone replacement therapy, trichomoniasis and, 543
Human immunodeficiency virus infection
East Africa, sexual transmission of hepatitis B in, 121 cytomegalovirus seropositivity in, sexual behavior and, 582
Estrogen replacement therapy, trichomoniasis and, 543 hepatitis B and, 211
E test, for N. gonorrhoeae susceptibility to azithromycin, 257 natural history of, in women vs. men, 77
neurocognitive impairment in, STD history and, 398
oral HPV infection in, 23
F
perinatal transmission of, maternal chlamydial and gonococcal
Fellatio cervicitis and, 495
acquisition of gonorrhea and nongonococcal urethritis by, in male persons at high risk for, sexual behavior of partners of, 461
homosexuals, 272 seroprevalence of, risk behaviors and, in Canada, 487
STD incidence and risk factors in, 251
acquisition of nongonococcal urethritis by, in heterosexual males, 449
testing for, in STD clinic population, 347
Female sex workers. See Commercial sex workers
type 1, genital ulcer disease and, in Kenyan sex workers, 387
Field studies, new paradigms for, 310 (editorial)
Human papiliomavirus
Finland, N. gonorrhoeae drug resistance in, 576 exposure to, genital warts as marker of, 567
First-void urine PCR test, for C. trachomatis, 343 type-specific prevalence of, in Greece, 469
Fluoroquinolones, N. gonorrhoeae resistance to, 247 Human papillomavirus DNA, in urine of males with condyloma acu-
in Phillipines, 2 minatum, 567
in Thailand, 142 Human papillomavirus infection. See also Genital warts
in Aboriginal vs. non-Aboriginal Canadian women, 293
after treatment for cervical dysplasia, 456
G
Hungary, chlamydial infection in, in low-risk population, 538
Gay men, acquisition of gonorrhea and nongonococcal urethritis by
fellatio in, 272
Genital herpes. See Herpes simplex virus infection
Genital ulcer disease Immunization, for genital herpes, acceptability of, 555
Infant, low birth weight, trichomoniasis and, 353
HIV infection risk and, 436
Intercourse. See also Sexual behavior
in Kenyan prostitutes, 387
anal, condoms in, 11
Genital warts. See also Human papillomavirus infection
Interferon-gamma, in chlamydial infection, 38
in females, risk factors for, 567 Interleukin-5, in chlamydial infection, 38
in males, HPV DNA in urine in, 165 International Union Against Sexually Transmitted Infections, 606
Gonococcal cervicitis, in pregnant women, in Thailand, 495 Intravenous drug abuse. See also Substance use/abuse
Gonococcal infection. See also Gonorrhea; Neisseria gonorrhoeae condom use and, 204
molecular epidemiology of, 409 Iron, H. ducreyi virulence and, 64
Gonorrhea. See also Neisseria gonorrhoeae
epidemiology of, sexual partnership networks in, 45 J
in male homosexuals, acquisition of by fellatio, 272
molecular epidemiology of, 409 Japan, cervical Mycoplasma genitalium in, 284
partner referral by patients with, 334
screening for K
algorithm for, for high-risk groups in developing countries, 109
noncompliance with follow-up recommendations after, 181 Kanamycin, N. gonorrhoeae resistance to, in Thailand, 142
Greece Kenya
N. gonorrhoeae antimicrobial sensitivity in, 378 female sex workers in
type-specific prevalence of genital HPV in, 469 genital ulcer disease in, 387
safety of nonoxynol-9 vaginal gel in, 279
truck drivers in, H. ducreyi antibody in, 267
H
Haemophilus ducreyi L
antibody to, in Kenyan truck drivers, 267 Laboratory compliance, with chlamydia notification requirements, in
virulence of, iron and, 64 Australia, 84
HBsAG, in HIV test seekers, 211 Low birth weight, trichomoniasis and, 353
Hepatitis B
markers of, among male HIV test seekers, 211
M
sexual transmission of
in Mexico, 211 Markers, for hepatitis B, in HIV test seekers, 211
in Tanzania, 121 Mathematical models, utility of, 201 (editorial)
Hepatitis C, in STD high-risk population, 533 Menopause, estrogen replacement therapy in, trichomoniasis and, 543
Herpes simplex virus infection Metronidazole
612 INDEX OF SUBJECTS Sexually Transmitted Diseases ¢ November, 1997
oral, for trichomoniasis, vs. clotrimazole vaginal tablets and AVC Polymerase chain reaction (PCR)
suppositories, 156 for C. trachomatis, urine tests for, 343, 429
with zinc sulfate douche, for trichomoniasis, 116 vs. virus culture, for HSV infection diagnosis, 176
Mexico, hepatitis B markers in HIV test seekers in, 211 Pregnancy
Minority adolescents, sexual networks of, 327 chlamydial and gonococcal cervicitis in, in Thailand, 495
Mycoplasma genitalium, cervical, in Japan, 284 syphilis in, single benzathine penicillin injection for, 94
trichomoniasis in, 361 (editorial)
N low birth weight and preterm delivery and, 353
Preterm delivery, trichomoniasis and, 353
Neisseria gonorrhoeae. See also Gonorrhea Prisoners, female, syphilis control for, 218
AHUA-1,2 phenotype of, genomic heterogeneity of, 561 Procaine penicillin, daily injection of, for syphilis-treponemal infec-
azithromycin susceptibility testing for, E-test vs. agar dilution methods tion, compliance with, 127
for, 257 Prostitutes. See Commercial sex workers
DNA probe test vs. culture for, 422
drug resistance/susceptibility of, 247
R
in Finland, 576
in Greece, 378 Race
molecular epidemiology and, 409 adolescent sexual networks and, 327
in Phillipines, 2 STD reporting and, 552 (letter)
in South Africa, 11 trichomoniasis in pregnancy and, 353
in Thailand, 142 Raft cultures, in evaluation of vaginal microbicidal agents, 69
in West and Central Africa, 32
Rapid plasma reagin (RPR) test, for syphilis, in female prisoners, 218
in pregnant women, in Thailand, 495
Reporting
Neonate, low birth weight, trichomoniasis and, 353
of chlamydial infection, in Australia, 84
Networks
of STDs, race and, 552 (letter)
in gonorrhea epidemiology, 45
Risk factors
of minority adolescents, 327
for bacterial vaginosis, 241
STD reporting and, 552 (letter)
for chlamydial infection, 241
Neurocognitive impairment, in HIV infection, STD history and, 398
for HIV infection, genital ulcer disease as, 436
Neurosyphilis, daily procaine penicillin for, compliance with, 127
for nongonococcal urethritis, 449
Noncompliance, after positive screening for gonorrhea and chlamydia,
181 for oral HPV infection, 23
Nongonococcal urethritis residence in high-risk neighborhood as, 322
azithromycin for, 57 (letter) for STDs, 102
in heterosexual men, risk factors for, 449 in HIV infection, 251
in male homosexuals, acquisition of by fellatio, 272 in Zimbabwe, 528
Nonoxynol-9 vaginal gel, safety of, in Kenyan prostitutes, 279 substance use as, in female adolescents, 313, 320 (editorial)
Notification Risk index, for STDs, 102
for chlamydial infection, in Australia, 84
partner
cost-benefit ratio for, 511, 519 (editorial)
for PID prevention, 287 Screening
for syphilis, 511, 519 (editorial) for adolescents, 90
for chlamydial infection
O algorithm for, for high-risk groups in developing countries, 109
in men, 587
Ofloxacin, N. gonorrhoeae resistance to, 247 noncompliance with follow-up recommendations after, 181
Oral human papillomavirus infection, risk factors for, 23 performance and cost-effectiveness of, 131
Organotypic raft cultures, in evaluation of vaginal microbicidal agents, in Turkish sex workers, 573
69 for gonorrhea
algorithm for, for high-risk groups in developing countries, 109
noncompliance with follow-up recommendations after, 181
P
for syphilis, 227 (editorial)
Pap smear, abnormal, genital warts and, 567 Self-treatment, of STDs, 372
Partner networks, of minority adolescents, 327 in Thai sex workers, 593
Partner notification Sex, casual travel, high-risk behavior and, 418
cost-benefit ratio for, 511, 519 (editorial) Sexual behavior. See also Risk factors
for PID prevention, 287 assessment of, in adolescents, 90
for syphilis, 511, 519 (editorial) high-risk, in women with history of casual travel sex, 418
Partner referral, by patients with gonorrhea and chlamydial infection, HIV seroprevalence and, in Canada, 487
334 male, CMV seropositivity in HIV infection and, 582
Pelvic inflammatory disease (PID), prevention of, partner notification of partners of persons at high risk for HIV infection, 461
for, 287 self-reporting of by female adolescents, validity of, 261
Penicillin substance use and
daily injection of, for syphilis-treponemal infection, compliance with, in female adolescents, 313, 320 (editorial)
127 in high-risk neighborhoods, 322
N. gonorrhoeae resistance to. See Neisseria gonorrhoeae, drug surveys of, with integrated STD testing, 299, 552 (letter)
resistance/susceptibility of Sexual intercourse, anal, condoms in, 11
single injection of, for syphilis, in pregnancy, 94 Sexually transmitted disease clinic patients, motivation for HIV testing
Phillipines, drug-resistant N. gonorrhoeae in, 2 in, 347
Physicians, STD management by, in urban Canadian center, 393 Sexually transmitted disease clinics
24 e No. 10 INDEX OF SUBJECTS 613
delayed presentation to, 443 chlamydial and gonococcal cervicitis in pregnant women in, 495
use of and need for, 599 commercial sex workers in
Sexually transmitted diseases (STDs). See also specific diseases multiple condom use by, 546, 550 (editorial)
delayed presentation to clinics in, 443 self-medication for STDs in, 593
in developing countries, public-private initiatives for, 61 (editorial) gonococcal resistance in, 142
in drug-using prostitutes, incidence trends for, 363 Thiamphenicol, N. gonorrhoeae resistance to, in Thailand, 142
Travel, casual sex during, high-risk behavior and, 418
high-risk population for, hepatitis C in, 533
Treatment. See also Self-treatment
HIV-related neurocognitive impairment and, 398
delay in seeking, 443
incidence and risk factors for, in HIV infection, 251
Treponemal infection, daily procaine penicillin for, compliance with,
oral HPV infection as, 23 127
physicians’ management of, in urban Canadian center, 393 Trichomoniasis
prevention of, in adolescents, 90 estrogen replacement therapy and, 543
reporting of, sexual network data and, 552 (letter) oral metronidazole for, vs. clotrimazole vaginal tablets and AVC
risk factors for, in Zimbabwe, 528 suppositories, 156
risk index for, 102 in pregnancy, 361 (editorial)
self-treatment of, 372 low birth weight and preterm delivery and, 353
in Thai sex workers, 593 zinc sulfate douche and metronidazole for, 116
surveillance and field studies of, new paradigms for, 310 (editorial) Tuberculosis, STDs and, 8
tuberculosis and, 8 Turkey, chlamydial infection in sex workers in, screening for, 573
urine tests for, integrated with behavioral surveys, 299, 552 (letter)
Sexually Transmitted Diseases, increased number of issues of, 1 (edi- U
torial)
Sexual networks Ulcers, genital. See Genital ulcer disease
in gonorrhea epidemiology, 45 Unsafe sex practices. See High-risk behavior; Sexual behavior
Urethritis, nongonococcal
of minority adolescents, 327
azithromycin for, 57 (letter)
STD reporting and, 552 (letter)
in heterosexual men, risk factors for, 449
Sex workers. See Commercial sex workers
in male homosexuals, acquisition of by fellatio, 272
South Africa, N. gonorrhoeae antibiotic susceptibility in, 11 Urine tests
Substance use/abuse for PCR test for C. trachomatis, 343, 429
condom use and, 204 for STDs, integrated with behavioral surveys, 299, 552 (letter)
sexual behavior and
in female adolescents, 313, 320 (editorial)
Vv
in high-risk neighborhoods, 322
Sulfanilamide, in AVC suppositories, for trichomoniasis, vs. oral Vaccination, for genital herpes, acceptability of, 555
metronidazole, 156 Vaginal microbicidal agents, in vitro evaluation of, organotypic raft
Surveillance studies, new paradigms for, 310 (editorial) cultures for, 69
Surveys, behavioral, with integrated STD testing, 299, 552 (letter) Vaginal smears, self-obtained sequential, utility of, 236
Syphilis Vaginal trichomoniasis. See Trichomoniasis
antibiotics for, 227 (editorial) Vaginosis, bacterial, self-obtained sequential vaginal smears for, util-
control of, in female prisoners, 218 ity of, 236
daily procaine penicillin for, compliance with, 127 Valacyclovir, vs. acyclovir, for first-episode genital herpes, 481
early, epidemiology of, 475 Virus culture, vs. PCR, for HSV infection diagnosis, 176
Viruses, small, condoms as barriers to, 161
natural history of, 185
partner notification for, 511, 519 (editorial)
screening for, 227 (editorial) Ww
single benzathine penicillin injection for, in pregnancy, 94
West Africa, N. gonorrhoeae resistance in, 32
transmission dynamics of, 185
Women
casual travel sex in, high-risk behavior and, 418
T commercial sex workers. See Commercial sex workers
HIV infection natural history in, 77
Tanzania, sexual transmission of hepatitis B in, 121
Tetracycline, N. gonorrhoeae resistance to. See Neisseria gonor- Z
rhoeae, drug resistance/susceptibility of
in Phillipines, 2 Zimbabwe, STD risk factors in, 528
Thailand Zinc sulfate douche, with metronidazole, for trichomoniasis, 116
STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970: Section 3685, Title 39, United States Code) Date of Filing—October
1, 1997. Title of Publication—Sexually Transmitted Diseases; Frequency of Issue—10 issues annually; Annual Subscription Price—$203.00; Location of Known Office
of Publication—Lippincott-Raven Publishers, 12107 Insurance Way, Suite 114, Hagerstown, MD 21740; Location of the Headquarters or General Business Offices of
the Publisher—227 East Washington Square, Philadelphia, PA 19106; Publisher—Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106;
Editor—Julius Schacter, PhD, Room 416/Building #30, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110. Assistant Editor—Jeanne
Moncada, Room 416/Building #30, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94119. Owner—American Sexually Transmitted Diseases
Association, c/o Denver Public Health, 605 Bannock Street, Denver, CO 80204. Known Bondholders, Mortgagees, and other security holders owning or holding 1
percent or more of total amount of bonds, mortgages, or other securities—none. A. Total no. copies printed (net press run), average 2,200, actual 2,400; B. Paid
circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 1,422, actual 1,386; C. Total
paid circulation, average 1,422, actual 1,386; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 94, actual 85,
E. Total distribution (sum of C and D), average 1,516, actual 1,471; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 684,
actual 929; 2. Returns from news agents, none: G. Total (sum of E and F—should equal net press runs shown in A), average 2,200, actual 2,400. I certify that the
statements made by me above are correct and complete. Beverly Dietrich, Circulation Director.